Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Nontuberculous mycobacterial pulmonary disease and Aspergillus co-infection: Bonnie and Clyde?

Geurts K, Zweijpfenning SMH, Pennings LJ, Schildkraut JA, Boeree MJ, Magis-Escurra C, van der Lee H, Verweij PE, Hoefsloot W, van Ingen J.

Eur Respir J. 2019 Apr 7. pii: 1900117. doi: 10.1183/13993003.00117-2019. [Epub ahead of print] No abstract available.

PMID:
30956203
2.

Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis.

Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, Jhun BW, Koh WJ, Namkoong H, Park J, Thomson R, van Ingen J, Zweijpfenning SMH, Yim JJ.

Eur Respir J. 2019 Mar 17. pii: 1801991. doi: 10.1183/13993003.01991-2018. [Epub ahead of print]

PMID:
30880280
3.

High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.

Seijger C, Hoefsloot W, Bergsma-de Guchteneire I, Te Brake L, van Ingen J, Kuipers S, van Crevel R, Aarnoutse R, Boeree M, Magis-Escurra C.

PLoS One. 2019 Mar 14;14(3):e0213718. doi: 10.1371/journal.pone.0213718. eCollection 2019.

4.

Implementation of Semiautomated Antimicrobial Susceptibility Interpretation Hardware for Nontuberculous Mycobacteria May Overestimate Susceptibility.

Rockland M, Ruth MM, Aalders N, Pennings L, Hoefsloot W, Wattenberg M, van Ingen J.

J Clin Microbiol. 2019 Mar 28;57(4). pii: e01756-18. doi: 10.1128/JCM.01756-18. Print 2019 Apr.

PMID:
30760530
5.

A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.

Ruth MM, Sangen JJN, Remmers K, Pennings LJ, Svensson E, Aarnoutse RE, Zweijpfenning SMH, Hoefsloot W, Kuipers S, Magis-Escurra C, Wertheim HFL, van Ingen J.

J Antimicrob Chemother. 2019 Apr 1;74(4):935-943. doi: 10.1093/jac/dky526.

PMID:
30649327
6.

Adriaan Manten, 1918-2017.

van Ingen J.

Int J Tuberc Lung Dis. 2018 Dec 1;22(12):1528. doi: 10.5588/ijtld.18.0430. No abstract available.

PMID:
30606330
7.

Successful lung transplantation for chronic Mycobacterium abscessus infection in advanced cystic fibrosis, a case series.

Raats D, Lorent N, Saegeman V, Vos R, van Ingen J, Verleden G, Van Raemdonck D, Dupont L.

Transpl Infect Dis. 2019 Apr;21(2):e13046. doi: 10.1111/tid.13046. Epub 2019 Jan 13.

PMID:
30597699
8.

Clofazimine does not lead to significant QT interval prolongation: a multicentre study.

Zweijpfenning SMH, van Groningen H, van Ingen J, Magis-Escurra C, Boeree MJ, Wagner D, Bax H, Andrejak C, Wener R, Rahman A, Kunst H, Lorent N, Brouwer MA, Hoefsloot W; NTM-NET.

Eur Respir J. 2018 Nov 1;52(5). pii: 1801386. doi: 10.1183/13993003.01386-2018. Print 2018 Nov. No abstract available.

PMID:
30385602
9.

A definition of the Mycobacterium avium complex for taxonomical and clinical purposes, a review.

van Ingen J, Turenne CY, Tortoli E, Wallace RJ Jr, Brown-Elliott BA.

Int J Syst Evol Microbiol. 2018 Nov;68(11):3666-3677. doi: 10.1099/ijsem.0.003026. Epub 2018 Sep 19.

PMID:
30231956
10.

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT): A Prospective, Open-Label, Randomized Study.

Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group.

Am J Respir Crit Care Med. 2018 Sep 14. doi: 10.1164/rccm.201807-1318OC. [Epub ahead of print]

PMID:
30216086
11.

Dissemination of localized Mycobacterium malmoense infection in an immunocompromised patient.

Zweijpfenning SMH, Schipper L, Duurkens VAM, Harbers JB, van Ingen J, Hoefsloot W.

Int J Infect Dis. 2018 Nov;76:35-37. doi: 10.1016/j.ijid.2018.08.019. Epub 2018 Sep 7.

12.

Minocycline Has No Clear Role in the Treatment of Mycobacterium abscessus Disease.

Ruth MM, Sangen JJN, Pennings LJ, Schildkraut JA, Hoefsloot W, Magis-Escurra C, Wertheim HFL, van Ingen J.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01208-18. doi: 10.1128/AAC.01208-18. Print 2018 Oct.

13.

Geographic Distribution of Nontuberculous Mycobacteria Isolated from Clinical Specimens: A Systematic Review.

Zweijpfenning SMH, Ingen JV, Hoefsloot W.

Semin Respir Crit Care Med. 2018 Jun;39(3):336-342. doi: 10.1055/s-0038-1660864. Epub 2018 Aug 2.

PMID:
30071548
14.

The stability of antimycobacterial drugs in media used for drug susceptibility testing.

Schoutrop ELM, Brouwer MAE, Jenniskens JCA, Ferro BE, Mouton JW, Aarnoutse RE, van Ingen J.

Diagn Microbiol Infect Dis. 2018 Dec;92(4):305-308. doi: 10.1016/j.diagmicrobio.2018.06.015. Epub 2018 Jun 27.

PMID:
30025972
15.

Mycobacterium avium complex bacteria remain viable in sputum during storage and refrigeration.

Pennings LJ, Zweijpfenning S, Ruth MM, Wattenberg M, Boeree MJ, Hoefsloot W, van Ingen J.

Diagn Microbiol Infect Dis. 2018 Dec;92(4):309-310. doi: 10.1016/j.diagmicrobio.2018.06.017. Epub 2018 Jun 27.

PMID:
30025970
16.

Linking minimum inhibitory concentrations to whole genome sequence-predicted drug resistance in Mycobacterium tuberculosis strains from Romania.

Ruesen C, Riza AL, Florescu A, Chaidir L, Editoiu C, Aalders N, Nicolosu D, Grecu V, Ioana M, van Crevel R, van Ingen J.

Sci Rep. 2018 Jun 26;8(1):9676. doi: 10.1038/s41598-018-27962-5.

17.

Can epilepsy be treated by antibiotics?

Braakman HMH, van Ingen J.

J Neurol. 2018 Aug;265(8):1934-1936. doi: 10.1007/s00415-018-8943-3. Epub 2018 Jun 21.

PMID:
29931545
18.

QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study.

Guglielmetti L, Tiberi S, Burman M, Kunst H, Wejse C, Togonidze T, Bothamley G, Lange C; TBnet; of the TBnet QTc survey.

Eur Respir J. 2018 Aug 16;52(2). pii: 1800537. doi: 10.1183/13993003.00537-2018. Print 2018 Aug. No abstract available.

PMID:
29880656
19.

Clinical, radiological and molecular features of Mycobacterium kansasii pulmonary disease.

Bakuła Z, Kościuch J, Safianowska A, Proboszcz M, Bielecki J, van Ingen J, Krenke R, Jagielski T.

Respir Med. 2018 Jun;139:91-100. doi: 10.1016/j.rmed.2018.05.007. Epub 2018 May 9.

PMID:
29858008
20.

MALDI Spectra Database for Rapid Discrimination and Subtyping of Mycobacterium kansasii.

Murugaiyan J, Lewin A, Kamal E, Bakuła Z, van Ingen J, Ulmann V, Unzaga Barañano MJ, Humięcka J, Safianowska A, Roesler UH, Jagielski T.

Front Microbiol. 2018 Apr 3;9:587. doi: 10.3389/fmicb.2018.00587. eCollection 2018.

21.

Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement.

van Ingen J, Aksamit T, Andrejak C, Böttger EC, Cambau E, Daley CL, Griffith DE, Guglielmetti L, Holland SM, Huitt GA, Koh WJ, Lange C, Leitman P, Marras TK, Morimoto K, Olivier KN, Santin M, Stout JE, Thomson R, Tortoli E, Wallace RJ Jr, Winthrop KL, Wagner D; for NTM-NET.

Eur Respir J. 2018 Mar 22;51(3). pii: 1800170. doi: 10.1183/13993003.00170-2018. Print 2018 Mar. No abstract available.

PMID:
29567726
22.

Molecular typing of Mycobacterium kansasii using pulsed-field gel electrophoresis and a newly designed variable-number tandem repeat analysis.

Bakuła Z, Brzostek A, Borówka P, Żaczek A, Szulc-Kiełbik I, Podpora A, Parniewski P, Strapagiel D, Dziadek J, Proboszcz M, Bielecki J, van Ingen J, Jagielski T.

Sci Rep. 2018 Mar 13;8(1):4462. doi: 10.1038/s41598-018-21562-z.

23.

Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii.

Bakuła Z, Modrzejewska M, Pennings L, Proboszcz M, Safianowska A, Bielecki J, van Ingen J, Jagielski T.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01788-17. doi: 10.1128/AAC.01788-17. Print 2018 Apr.

24.

A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study.

Walker TM, Merker M, Knoblauch AM, Helbling P, Schoch OD, van der Werf MJ, Kranzer K, Fiebig L, Kröger S, Haas W, Hoffmann H, Indra A, Egli A, Cirillo DM, Robert J, Rogers TR, Groenheit R, Mengshoel AT, Mathys V, Haanperä M, Soolingen DV, Niemann S, Böttger EC, Keller PM; MDR-TB Cluster Consortium.

Lancet Infect Dis. 2018 Apr;18(4):431-440. doi: 10.1016/S1473-3099(18)30004-5. Epub 2018 Jan 8. Erratum in: Lancet Infect Dis. 2018 Jan 10;:.

26.

New insights in the treatment of nontuberculous mycobacterial pulmonary disease.

Ruth MM, van Ingen J.

Future Microbiol. 2017 Oct;12:1109-1112. doi: 10.2217/fmb-2017-0144. Epub 2017 Sep 20. No abstract available.

27.

Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.

Zweijpfenning S, Kops S, Magis-Escurra C, Boeree MJ, van Ingen J, Hoefsloot W.

Respir Med. 2017 Oct;131:220-224. doi: 10.1016/j.rmed.2017.08.031. Epub 2017 Sep 1.

PMID:
28947034
28.

Treatment of Mycobacterium avium-intracellulare complex: a great leap forward.

Alffenaar JC, van Ingen J.

J Antimicrob Chemother. 2017 Sep 1;72(suppl_2):i1-i2. doi: 10.1093/jac/dkx310. No abstract available.

PMID:
28922812
29.

Reinstating Mycobacterium massiliense and Mycobacterium bolletii as species of the Mycobacterium abscessus complex.

Adekambi T, Sassi M, van Ingen J, Drancourt M.

Int J Syst Evol Microbiol. 2017 Aug;67(8):2726-2730. doi: 10.1099/ijsem.0.002011. Epub 2017 Aug 18.

PMID:
28820087
30.

Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study.

van Ingen J, Kohl TA, Kranzer K, Hasse B, Keller PM, Katarzyna Szafrańska A, Hillemann D, Chand M, Schreiber PW, Sommerstein R, Berger C, Genoni M, Rüegg C, Troillet N, Widmer AF, Becker SL, Herrmann M, Eckmanns T, Haller S, Höller C, Debast SB, Wolfhagen MJ, Hopman J, Kluytmans J, Langelaar M, Notermans DW, Ten Oever J, van den Barselaar P, Vonk ABA, Vos MC, Ahmed N, Brown T, Crook D, Lamagni T, Phin N, Smith EG, Zambon M, Serr A, Götting T, Ebner W, Thürmer A, Utpatel C, Spröer C, Bunk B, Nübel U, Bloemberg GV, Böttger EC, Niemann S, Wagner D, Sax H.

Lancet Infect Dis. 2017 Oct;17(10):1033-1041. doi: 10.1016/S1473-3099(17)30324-9. Epub 2017 Jul 12.

PMID:
28711585
31.

Nifurtimox Is Ineffective against Drug-Resistant Mycobacteria.

Ruth MM, Sangen JJN, Wertheim HFL, van Ingen J.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01233-17. doi: 10.1128/AAC.01233-17. Print 2017 Sep. No abstract available.

32.

Patient ethnicity and causative species determine the manifestations of anti-interferon-gamma autoantibody-associated nontuberculous mycobacterial disease: a review.

Hase I, Morimoto K, Sakagami T, Ishii Y, van Ingen J.

Diagn Microbiol Infect Dis. 2017 Aug;88(4):308-315. doi: 10.1016/j.diagmicrobio.2017.05.011. Epub 2017 May 18. Review.

PMID:
28633901
33.

Draft Genome Sequences of Mycobacterium kansasii Clinical Strains.

Borówka P, Lach J, Bakuła Z, van Ingen J, Safianowska A, Brzostek A, Dziadek J, Strapagiel D, Jagielski T.

Genome Announc. 2017 Jun 1;5(22). pii: e00406-17. doi: 10.1128/genomeA.00406-17.

34.

Disseminated Mycobacterium abscessus infection in a peritoneal dialysis patient.

Mooren VHJF, Bleeker MWP, van Ingen J, Hermans MHA, Wever PC.

IDCases. 2017 May 4;9:6-7. doi: 10.1016/j.idcr.2017.05.001. eCollection 2017.

35.

Correction: High Rates of Non-Tuberculous Mycobacteria Isolation in Mozambican Children with Presumptive Tuberculosis.

López-Varela E, García-Basteiro AL, Augusto OJ, Fraile O, Bulo H, Ira T, Gondo K, van Ingen J, Naniche D, Sacarlal J, Alonso PL.

PLoS One. 2017 Apr 6;12(4):e0175613. doi: 10.1371/journal.pone.0175613. eCollection 2017.

36.

FATE: the new partnership to Fight Against TB in Central and Eastern Europe.

Jagielski T; Partnership to Fight Against TB in Central and Eastern Europe (FATE).

Lancet Infect Dis. 2017 Apr;17(4):363. doi: 10.1016/S1473-3099(17)30120-2. No abstract available.

PMID:
28346172
37.

Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases.

van Ingen J, Wagner D, Gallagher J, Morimoto K, Lange C, Haworth CS, Floto RA, Adjemian J, Prevots DR, Griffith DE; NTM-NET.

Eur Respir J. 2017 Feb 15;49(2). pii: 1601855. doi: 10.1183/13993003.01855-2016. Print 2017 Feb. No abstract available.

38.

MST1R mutation as a genetic cause of Lady Windermere syndrome.

Becker KL, Arts P, Jaeger M, Plantinga TS, Gilissen C, van Laarhoven A, van Ingen J, Veltman JA, Joosten LA, Hoischen A, Netea MG, Iseman MD, Chan ED, van de Veerdonk FL.

Eur Respir J. 2017 Jan 18;49(1). pii: 1601478. doi: 10.1183/13993003.01478-2016. Print 2017 Jan. No abstract available.

39.

High Rates of Non-Tuberculous Mycobacteria Isolation in Mozambican Children with Presumptive Tuberculosis.

López-Varela E, García-Basteiro AL, Augusto OJ, Fraile O, Bulo H, Ira T, Gondo K, van Ingen J, Naniche D, Sacarlal J, Alonso PL.

PLoS One. 2017 Jan 17;12(1):e0169757. doi: 10.1371/journal.pone.0169757. eCollection 2017. Erratum in: PLoS One. 2017 Apr 6;12 (4):e0175613.

40.

Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.

Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, Verma D, Hill E, Drijkoningen J, Gilligan P, Esther CR, Noone PG, Giddings O, Bell SC, Thomson R, Wainwright CE, Coulter C, Pandey S, Wood ME, Stockwell RE, Ramsay KA, Sherrard LJ, Kidd TJ, Jabbour N, Johnson GR, Knibbs LD, Morawska L, Sly PD, Jones A, Bilton D, Laurenson I, Ruddy M, Bourke S, Bowler IC, Chapman SJ, Clayton A, Cullen M, Daniels T, Dempsey O, Denton M, Desai M, Drew RJ, Edenborough F, Evans J, Folb J, Humphrey H, Isalska B, Jensen-Fangel S, Jönsson B, Jones AM, Katzenstein TL, Lillebaek T, MacGregor G, Mayell S, Millar M, Modha D, Nash EF, O'Brien C, O'Brien D, Ohri C, Pao CS, Peckham D, Perrin F, Perry A, Pressler T, Prtak L, Qvist T, Robb A, Rodgers H, Schaffer K, Shafi N, van Ingen J, Walshaw M, Watson D, West N, Whitehouse J, Haworth CS, Harris SR, Ordway D, Parkhill J, Floto RA.

Science. 2016 Nov 11;354(6313):751-757. doi: 10.1126/science.aaf8156.

41.

Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.

Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6374-6. doi: 10.1128/AAC.00990-16. Print 2016 Oct.

42.

Draft Genome Sequences of Mycobacterium kansasii Strains 1010001454, 1010001458, 1010001468, 1010001493, 1010001495, and 1010001469, Isolated from Environmental Sources.

Strapagiel D, Borówka P, Marciniak B, Bakuła Z, van Ingen J, Safianowska A, Brzostek A, Dziadek J, Jagielski T.

Genome Announc. 2016 Jun 2;4(3). pii: e00456-16. doi: 10.1128/genomeA.00456-16.

43.

Hydrogen cyanide emission in the lung by Staphylococcus aureus.

Neerincx AH, Linders YA, Vermeulen L, Belderbos RA, Mandon J, van Mastrigt E, Pijnenburg MW, van Ingen J, Mouton JW, Kluijtmans LA, Wevers RA, Harren FJ, Cristescu SM, Merkus PJ.

Eur Respir J. 2016 Aug;48(2):577-9. doi: 10.1183/13993003.02093-2015. Epub 2016 May 26. No abstract available.

44.

Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Fails To Identify Nontuberculous Mycobacteria from Primary Cultures of Respiratory Samples.

van Eck K, Faro D, Wattenberg M, de Jong A, Kuipers S, van Ingen J.

J Clin Microbiol. 2016 Jul;54(7):1915-1917. doi: 10.1128/JCM.00304-16. Epub 2016 May 4.

45.

Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease.

Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T.

Antimicrob Agents Chemother. 2016 May 23;60(6):3779-85. doi: 10.1128/AAC.02821-15. Print 2016 Jun.

46.

Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease.

Ferro BE, Srivastava S, Deshpande D, Pasipanodya JG, van Soolingen D, Mouton JW, van Ingen J, Gumbo T.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2895-900. doi: 10.1128/AAC.03112-15. Print 2016 May.

47.

Methodological and Clinical Aspects of the Molecular Epidemiology of Mycobacterium tuberculosis and Other Mycobacteria.

Jagielski T, Minias A, van Ingen J, Rastogi N, Brzostek A, Żaczek A, Dziadek J.

Clin Microbiol Rev. 2016 Apr;29(2):239-90. doi: 10.1128/CMR.00055-15. Review.

48.

Proposal of a new method for subtyping of Mycobacterium kansasii based upon PCR restriction enzyme analysis of the tuf gene.

Bakuła Z, Modrzejewska M, Safianowska A, van Ingen J, Proboszcz M, Bielecki J, Jagielski T.

Diagn Microbiol Infect Dis. 2016 Apr;84(4):318-21. doi: 10.1016/j.diagmicrobio.2015.12.009. Epub 2015 Dec 17.

PMID:
26830053
49.

Deficient interleukin-17 production in response to Mycobacterium abscessus in cystic fibrosis.

Becker KL, van Ingen J, Ten Oever J, Merkus PJ, Ferwerda G, Netea MG, Magis-Escurra C, Reijers MH, van de Veerdonk FL.

Eur Respir J. 2016 Mar;47(3):990-3. doi: 10.1183/13993003.00446-2015. Epub 2016 Jan 7. No abstract available.

50.

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary.

Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS.

Thorax. 2016 Jan;71(1):88-90. doi: 10.1136/thoraxjnl-2015-207983.

Supplemental Content

Loading ...
Support Center